The FDA has approved doripenem for injection (Doribax, Ortho-McNeil) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. Doripenem is active against a wide range of gram-positive and gram-negative bacteria, including Pseudomonas.
As an antibacterial carbapenem, doripenem is indicated as a single agent for the treatment of complicated intraabdominal infections caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Staphylococcus intermedius, Streptococcus con-stellatus, or Peptostreptococcus micros. It is also used to treat complicated urinary tract infections, caused by susceptible strains of E. coli, including cases with concurrent bacteremia, K. pneumoniae, Proteus mirabilis, P. aeruginosa, or Acinetobacter baumannii.
The approval of doripenem was based on results of two multicenter, prospective, randomized, double-blind clinical trials.
(Source: Ortho-McNeil, October 15,